NEW! Quarterly Update: Georgia CORE Investigator-Initiated Breast Cancer Trials

6/11/2009

Ruth O’Regan, MD, Associate Professor of Hematology and Oncology at the Emory Winship Cancer Institute, Director of Winship's Translational Breast Cancer Research Program and Georgia Cancer Coalition Distinguished Cancer Scholar, received a grant from Susan G. Komen for the Cure Greater Atlanta to promote minority accrual to Georgia CORE clinical trials. One component of the grant is to produce webcast updates for Georgia Investigators on the Investigator-Initiated breast cancer studies being conducted through the Georgia CORE Research Network. In this fourth series of the webcast updates, Dr. O'Regan details the rationale, study schema and status of the following studies:

• Randomized Phase II Trial of Sequential Docetaxel followed by Capecitabine versus Concomitant Docetaxel/Capecitabine as Induction Therapy for Early Stage Breast Cancer
• Phase II Neoadjuvant Trial of Trastuzumab in Combination with Dose-Dense ABI-007 (Abraxane) Followed by Vinorelbine for HER2 Overexpressing Early Stage Breast Cancer
• Phase II Trial of Gemcitabine and Oxaliplatin for ER-, PR-, HER2Neu- (Triple Negative) Metastatic Breast Cancer
• Phase II Trial of Pre-operative Docetaxel-Cytoxan (TC) in Patients with Hormone Receptor-Positive Cancers with Recurrance Scores greater than or equal to 25
• Randomized Phase II Trial of Pre-operative Docetaxel-Cytoxan (TC) and Exemestane in Patients with Hormone Receptor-Positive Cancers with Recurrence Scores less than 25

Please click here to view the educational video. **The video requires the most recent version of Real Player.

Please click here to download the Real Player software.